Aiolos/IKZF3 Antibody

Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Total protein from Jurkat cells and human tonsil was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-IkZF3 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: Aiolos/IKZF3 Antibody [NBP2-24495] - IKZF3 antibody was tested in Jurkat cells at a 1:40 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against DyLight 568 (Red) and DAPI (Blue), respectively.

Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Analysis of IKZF3 in human spleen lysate in the 1) absence and 2) presence of immunizing peptide using this antibody at 0.25 ug/mL.

• Reactivity: Hu, Pm
• Applications: WB, ICC/IF
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 1.0 mg/ml

Aiolos/IKZF3 Antibody Summary

• Immunogen: A portion of amino acids 350-400 of human IKZF3 was used as the immunogen.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: IKZF3
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.25 - 1.0 ug/mL
  • Immunocytochemistry/Immunofluorescence 1:100

Reactivity Notes

The amino acid sequence used as immunogen is 88% in dog, mouse and rat and 82% homologous in horse.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for Aiolos/IKZF3 Antibody

• AIO
• Aiolos
• IKAROS family zinc finger 3 (Aiolos)
• Ikaros family zinc finger protein 3
• IKZF3
• zinc finger protein Aiolos
• ZNFN1A3
• ZNFN1A3subfamily 1A, 3 (Aiolos)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Aiolos/IKZF3 Antibody (NBP2-24495)(5)

Publications using NBP2-24495

• Costa F, Vescovini R, Bolzoni M et al. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties Oncotarget 2017 Aug 08 [PMID: 28881793] (WB, Human)
• Uehara T, Minoshima Y, Sagane K et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat. Chem. Biol. Apr 24 2017 [PMID: 28437394]
• Nguyen TV, Li J, Lu CJ et al. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc. Natl. Acad. Sci. U.S.A. Mar 20 2017 [PMID: 28320958] (WB, Human)
• Gao S, Geng C, Song T et al. Activation of c-Abl kinase potentiates the anti-myeloma drug lenalidomide by promoting DDA1 recruitment to the CRL4 ubiquitin ligase J. Biol. Chem Jan 13 2017 [PMID: 28087699]
• Zhu YX, Braggio E, Shi CX et al. Identification of cereblon binding proteins and relationship with response and survival following pomalidomide and dexamethasone in multiple myeloma. Blood. 2014 Jun 09 [PMID: 24914135] (WB, Human)
  
  Details:
  Figs 3 & 5: IKZF1, IKZF3 or cerebron (CRBN), lentiviral infected human myeloma cell lines (HMCLs) and infected HMCLs treated with IKZF1, IKZF3 or CRBN ShRNAs, respecitvely. The specificity of the IKZF3 pAb was validated in IKZF3-infected HMCLs and in IKZF3-shRNA infected cells by WB (Figs 3 & 5). The IKZF3 pAb recognized IKZF3 in WB that had been co-IP'd using a CRBN antibody, thereby helping to demonstrate that IKZF3 is a CRNB binding protein (Fig 3D).

Bioinformatics

• Gene Symbol: IKZF3
• Uniprot:
  • Q9UKT9()